232 related articles for article (PubMed ID: 33154554)
1. Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy.
Wang CY; Sheng CC; Ma GL; Xu D; Liu XQ; Wang YY; Zhang L; Cui CL; Xu BH; Song YQ; Zhu J; Jiao Z
Acta Pharmacol Sin; 2021 Aug; 42(8):1368-1375. PubMed ID: 33154554
[TBL] [Abstract][Full Text] [Related]
2. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma.
Nie J; Wang C; Liu Y; Yang Q; Mei Q; Dong L; Li X; Liu J; Ku W; Zhang Y; Chen M; An X; Shi L; Brock MV; Bai J; Han W
J Clin Oncol; 2019 Jun; 37(17):1479-1489. PubMed ID: 31039052
[TBL] [Abstract][Full Text] [Related]
3. A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors.
Chung TK; Lee HA; Park SI; Oh DY; Lee KW; Kim JW; Kim JH; Woo A; Lee SJ; Bang YJ; Lee H
Clin Transl Sci; 2021 May; 14(3):990-1001. PubMed ID: 33382918
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
[TBL] [Abstract][Full Text] [Related]
5. Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1.
Song H; Liu X; Jiang L; Li F; Zhang R; Wang P
Recent Pat Anticancer Drug Discov; 2021; 16(3):312-332. PubMed ID: 33563158
[TBL] [Abstract][Full Text] [Related]
6. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR.
Sharma S; Mittapalli RK; Holen KD; Xiong H
Clin Pharmacokinet; 2015 Oct; 54(10):1071-81. PubMed ID: 25761639
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
Narwal R; Roskos LK; Robbie GJ
Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
[TBL] [Abstract][Full Text] [Related]
9. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies.
Yang F; Paccaly AJ; Rippley RK; Davis JD; DiCioccio AT
J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):479-494. PubMed ID: 33728546
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dosing strategy for pembrolizumab for oncology indications.
Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
[TBL] [Abstract][Full Text] [Related]
12. Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors.
Ahamadi M; Freshwater T; Prohn M; Li CH; de Alwis DP; de Greef R; Elassaiss-Schaap J; Kondic A; Stone JA
CPT Pharmacometrics Syst Pharmacol; 2017 Jan; 6(1):49-57. PubMed ID: 27863186
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and exposure-response of anti-programmed cell death protein-1 monoclonal antibody dostarlimab in advanced solid tumours.
Melhem M; Hanze E; Lu S; Alskär O; Visser S; Gandhi Y
Br J Clin Pharmacol; 2022 Sep; 88(9):4142-4154. PubMed ID: 35357027
[TBL] [Abstract][Full Text] [Related]
14. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
[TBL] [Abstract][Full Text] [Related]
15. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
Shen T; Zheng S; Geng L; Liu Z; Xu J; Lin B; Qian J; Zheng S
Technol Cancer Res Treat; 2020; 19():1533033820979703. PubMed ID: 33308041
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma.
Rathi C; Collins J; Struemper H; Opalinska J; Jewell RC; Ferron-Brady G
CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):851-863. PubMed ID: 34076364
[TBL] [Abstract][Full Text] [Related]
17. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia.
Lickliter JD; Gan HK; Voskoboynik M; Arulananda S; Gao B; Nagrial A; Grimison P; Harrison M; Zou J; Zhang L; Luo S; Lahn M; Kallender H; Mannucci A; Somma C; Woods K; Behren A; Fernandez-Penas P; Millward M; Meniawy T
Drug Des Devel Ther; 2020; 14():1177-1189. PubMed ID: 32256049
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy.
Wang C; Liu Y; Dong L; Li X; Yang Q; Brock MV; Mei Q; Liu J; Chen M; Shi F; Liu M; Nie J; Han W
Clin Cancer Res; 2021 May; 27(10):2782-2791. PubMed ID: 33674274
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease.
Li C; Shoji S; Beebe J
Br J Clin Pharmacol; 2018 Sep; 84(9):2059-2074. PubMed ID: 29776017
[TBL] [Abstract][Full Text] [Related]
20. Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma.
Gibiansky L; Passey C; Roy A; Bello A; Gupta M
J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):243-57. PubMed ID: 26993283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
